The True™ Flow Valvuloplasty Perfusion Catheter is an over-the-wire co-axial catheter with a balloon fixed at the tip. The balloon enables hemodynamic flow through its central orifice. The catheter is 110 cm long and has two lumens: one lumen is used to inflate and deflate the balloon and the other permits the use of a guidewire to position the catheter. The balloon inflation luer-lock hub (angled) connects to a syringe inflation device to deliver radiopaque contrast media for inflation. The quidewire luer-lock hub (straight) connects to the guidewire lumen. The balloon is non-compliant and is designed to reach a known diameter and length when inflated within the specified pressure range. Three radiopaque markers are embedded in the balloon wall. These bands are positioned at the proximal and distal balloon shoulders, and in the middle. These bands are provided for fluoroscopic positioning of the device across the aortic valve. Balloon catheter dimensions, nominal pressure, maximum inflation pressure, recommended introducer size, and maximum guidewire size are indicated on the package label.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study information for the True™ Flow Valvuloplasty Perfusion Catheter:

Note: The provided document is a 510(k) summary for a medical device, which focuses on demonstrating substantial equivalence to a predicate device rather than providing a detailed clinical study report proving a device meets specific clinical acceptance criteria in a human population. Therefore, many of the requested items related to human studies (sample sizes, expert qualifications, adjudication, MRMC) cannot be directly extracted from this document, as the "studies" mentioned are primarily non-clinical (in vitro) performance tests.

1. Table of Acceptance Criteria and Reported Device Performance

The document lists various performance data categories and concludes that the device "met all predetermined acceptance criteria of design verification and validation." However, it does not provide a specific table detailing the quantitative acceptance criteria for each test or the exact numerical performance results. It merely states that the criteria were met.

Therefore, the table below reflects what is reported in the document:

Performance Characteristic	Acceptance Criteria (as reported)	Reported Device Performance
Dimensional Testing	Predetermined criteria	Met criteria
Marker Band Alignment	Predetermined criteria	Met criteria
Dye Penetration	Predetermined criteria	Met criteria
Visual Inspection (Product)	Predetermined criteria	Met criteria
Visual Inspection (Packaging)	Predetermined criteria	Met criteria
Tip Morphology	Predetermined criteria	Met criteria
Trackability	Predetermined criteria	Met criteria
Sheath Compatibility	Predetermined criteria	Met criteria
Media Interaction	Predetermined criteria	Met criteria
Luer Interface	Predetermined criteria	Met criteria
Hub Stress	Predetermined criteria	Met criteria
Inflation/Deflation Time	Predetermined criteria	Met criteria
Fatigue to Failure	Predetermined criteria	Met criteria
Tip to Balloon Tensile	Predetermined criteria	Met criteria
Balloon Burst	Predetermined criteria	Met criteria
Catheter Leak	Predetermined criteria	Met criteria
Failure Mode	Predetermined criteria	Met criteria
Shaft Burst	Predetermined criteria	Met criteria
Catheter Elongation	Predetermined criteria	Met criteria
Hub to Shaft Tensile	Predetermined criteria	Met criteria
Balloon to Shaft Tensile	Predetermined criteria	Met criteria
Radiopacity	Predetermined criteria	Met criteria
Balloon Distensibility	Predetermined criteria	Met criteria
Perfusion Test	Predetermined criteria	Met criteria
Radial Force Test	Predetermined criteria	Met criteria
MEM Elution Test	Predetermined criteria	Met criteria
Kligman Maximization Test	Predetermined criteria	Met criteria
Intracutaneous Injection	Predetermined criteria	Met criteria
Systemic Injection Test	Predetermined criteria	Met criteria
Rabbit Pyrogen Test	Predetermined criteria	Met criteria
Hemolysis Rabbit Blood Contact	Predetermined criteria	Met criteria
Complement Activation Test	Predetermined criteria	Met criteria
Prothrombin Time Assay	Predetermined criteria	Met criteria
In Vitro Thrombogenicity	Predetermined criteria	Met criteria
In Vivo Thrombogenicity	Predetermined criteria	Met criteria
(Leveraged from Predicate)
Pouch Tensile	Predetermined criteria	Met criteria (by predicate)

2. Sample Size Used for the Test Set and the Data Provenance

Sample Size: The document does not specify the sample sizes used for each individual non-clinical (in vitro) test. It simply lists the types of tests performed.
Data Provenance: The tests are described as "in vitro tests," meaning they were conducted in a lab environment, not on human subjects. They are non-clinical studies. The country of origin of the data is not specified, but the applicant is "Bard Peripheral Vascular, Inc" located in Tempe, Arizona, USA.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

This information is not applicable and not provided in this document. Ground truth, in the context of expert consensus, typically refers to clinical data or interpretations by medical professionals. The studies described are primarily engineering and biocompatibility tests, not studies requiring expert clinical interpretation to establish ground truth.

4. Adjudication Method for the Test Set

This information is not applicable and not provided in this document. Adjudication methods (like 2+1 or 3+1) are usually for resolving discrepancies in expert opinions on clinical test data. Since the tests are in vitro performance tests, such a method is not relevant.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC comparative effectiveness study was not done. This document describes a medical device (a catheter), not an artificial intelligence (AI) system or a diagnostic imaging tool that would typically involve human readers.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

This information is not applicable. The device is a physical medical catheter, not an algorithm or AI system.

7. The Type of Ground Truth Used

For the in vitro performance and biocompatibility tests, the "ground truth" would be established by:

Engineering specifications and design requirements: For mechanical, dimensional, and functional tests (e.g., balloon burst, trackability, inflation/deflation time).
Standardized test methods and validated analytical techniques: For chemical, material interaction, and biological safety tests (e.g., MEM Elution, Rabbit Pyrogen Test, Thrombogenicity tests).
Comparison to predicate device performance benchmarks: The overall conclusion relies on demonstrating "substantial equivalence" to the predicate device.

8. The Sample Size for the Training Set

This information is not applicable and not provided. "Training set" refers to data used to train machine learning models. This document describes a physical medical device and its non-clinical testing, not an AI or machine learning product.

9. How the Ground Truth for the Training Set was Established

This information is not applicable. As stated above, there is no "training set" in the context of this device's evaluation.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 17, 2015

C.R. Bard, Inc. Aaron Conovaloff Regulatory Affairs Associate 1625 West 3rd St. Tempe, Arizona 85281-1740

Re: K142083

Trade/Device Name: True Flow Valvuloplasty Perfusion Catheter Regulation Number: 21 CFR 870.1255 Regulation Name: Balloon Aortic Valvuloplasty Catheter Regulatory Class: Class II Product Code: OZT Dated: March 3, 2015 Received: March 4, 2015

Dear Aaron Conovaloff.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR

{1}------------------------------------------------

Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

M.A. Hilleman

for

for Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known)

Device Name

True™ Flow Valvuloplasty Perfusion Catheter

Indications for Use (Describe)

The True™ Flow Valvuloplasty Perfusion Catheter is indicated for balloon aortic valvuloplasty.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

True™ Flow Valvuloplasty Perfusion Catheter

510(k) Summary 21 CFR 807.92

As required by the Safe Medical Devices Act of 1990, coded under Section 513, Part (I)(3)(A) of the Food, Drug and Cosmetic Act, a 510(k) summary upon which substantial equivalence determination is based is as follows:

Submitter Information:

Applicant:	Bard Peripheral Vascular, Inc1625 West 3rd StreetTempe, Arizona 85281
Phone:	480-350-6012
Fax:	480-449-2546
Contact:	Aaron Conovaloff, Regulatory Affairs Associate
Date:	August 14, 2014

Subject Device Name:

Device Trade Name:	True™ Flow Valvuloplasty PerfusionCatheter
Common or Usual Name:	Balloon Aortic Valvuloplasty/PercutaneousCatheter (21 CFR 870.1255, Product CodeOZT)
Classification:	Class II
Classification Panel:	Cardiovascular

Predicate Device:

. True Dilatation™ Balloon Valvuloplasty Catheter (K133569; cleared December 20, 2013)
Image /page/3/Picture/12 description: The image shows the word "BARD" in a stylized, sans-serif font. The letters are bold and outlined in black, giving them a distinct and modern appearance. The overall design is clean and simple, with a focus on readability and visual impact. The wordmark is likely a logo or branding element for a company or product named Bard.

{4}------------------------------------------------

Summary of Change:

The modifications from the predicate device, the True Dilatation™ Balloon Valvuloplasty Catheter, to the subject device, the True™ Flow Valvuloplasty Perfusion Catheter, include balloon design, balloon materials, catheter colorant, contraindications, and performance characteristics.

Device Description:

Attribute	True™ Flow Valvuloplasty PerfusionCatheterProduct Offering
Balloon Diameter(mm)	24
Balloon Length(cm)	3.5
Catheter ShaftLength (cm)	110
Introducer SheathCompatibility	18F

Image /page/4/Picture/8 description: The image shows the word "BARD" in a stylized, all-caps font. The letters are bold and outlined in black, giving them a distinct and modern look. The font choice appears to be custom, with unique angles and shapes forming each letter. The overall design is clean and minimalist, focusing on the word itself.

{5}------------------------------------------------

Indications for Use of Device:

The True™ Flow Valvuloplasty Perfusion Catheter is indicated for balloon aortic valvuloplasty.

Comparison of Indications for Use to Predicate Device:

The indications for use statement for the True™ Flow Valvuloplasty Perfusion Catheter does not raise any new issues of safety and effectiveness as demonstrated through the risk analysis process based on the proposed indications for use statement as compared to the predicate devices. Therefore, the subject device, the True™ Flow Valvuloplasty Perfusion Catheter, is substantially equivalent to the predicate device.

Technological Comparison to Predicate Device:

The True™ Flow Valvuloplasty Perfusion Catheter has the following similarities to the predicate device, the True Dilatation™ Balloon Valvuloplasty Catheter (clearance to market via K133569 on December 20, 2014):

. Same intended use
. Same indications for use
Same target population .
. Same operating principle
. Same fundamental scientific technology
. Same sterility assurance level and method of sterilization

The True™ Flow Valvuloplasty Perfusion Catheter incorporates the following new technological features as compared to the predicate device:

. Change in balloon design and materials to allow hemodynamic flow through the balloon while inflated
. Change in marker band materials and positions
. Change in catheter shaft color
Change in balloon proximal bond ●
Change in hub bonding materials .

Image /page/5/Picture/21 description: The image shows the word "BARD" in a stylized, outlined font. The letters are bold and geometric, with the "A" represented by a triangle without a horizontal crossbar. The overall design is clean and modern, with a focus on the shape and form of the letters.

{6}------------------------------------------------

. Change in strain relief design
Addition of packaging component ●

Performance Data:

To demonstrate substantial equivalence of the subject device to the predicate device, its technological characteristics and performance criteria were evaluated. Using FDA Guidance Documents on non-clinical testing of medical devices and internal Risk Assessment procedures, the following in vitro tests were performed on the subject device:

. Dimensional Testing
Marker Band Alignment .
Dye Penetration ●
Visual Inspection of Product .
Visual Inspection of Sterile Barrier Packaging Heat Seals
Tip Morphology .
. Trackability
Sheath Compatibility ●
Media Interaction
Luer Interface ●
Hub Stress .
Inflation/Deflation Time ●
. Fatigue to Failure
. Tip to Balloon Tensile
Balloon Burst ●
Catheter Leak ●
Failure Mode
Shaft Burst ●
Catheter Elongation ●
Hub to Shaft Tensile .
. Balloon to Shaft Tensile

Image /page/6/Picture/28 description: The image shows the word "BARD" in a stylized, all-caps font. The letters are bold and outlined in black, giving them a distinct and modern appearance. The font choice is geometric and sans-serif, contributing to the overall clean and professional look of the word. The image is simple and monochromatic, focusing solely on the word itself.

{7}------------------------------------------------

. Radiopacity
Balloon Distensibility ●
Perfusion Test
. Radial Force Test
MEM Elution Test ●
Kligman Maximization Test ●
Intracutaneous Injection Test ●
. Systemic Injection Test
Rabbit Pyrogen Test ●
Hemolysis Rabbit Blood Contact .
. Complement Activation Test
Prothrombin Time Assay ●
In Vitro Thrombogenicity .
In Vivo Thrombogenicity .

The following in vitro test was leveraged from the predicate True Dilatation™ device:

. Pouch Tensile
The results from these tests demonstrate that the technological characteristics and performance criteria of the True™ Flow Valvuloplasty Perfusion Catheter are substantially equivalent to the predicate device, and that it can perform in a manner equivalent to devices currently on the market for the same intended use.

Conclusions:

The subject device, the True™ Flow Valvuloplasty Perfusion Catheter, met all predetermined acceptance criteria of design verification and validation as specified by applicable standards, guidance, test protocols and/or customer inputs. The True™ Flow Valvuloplasty Perfusion Catheter is substantially equivalent to the legally marketed predicate device, the True Dilatation™ Balloon Valvuloplasty Catheter.

Image /page/7/Picture/22 description: The image shows the word "BARD" in a stylized, outlined font. Each letter is bold and connected to the adjacent letters, creating a continuous, block-like appearance. The font is sans-serif and has a modern, geometric feel.

Regulation Number and Section

§ 870.1255 Balloon aortic valvuloplasty catheter.

(a)
Identification. A balloon aortic valvuloplasty catheter is a catheter with a balloon at the distal end of the shaft, which is intended to treat stenosis in the aortic valve when the balloon is expanded.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The device must be demonstrated to be biocompatible.
(2) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components.
(3) Non-clinical performance evaluation must demonstrate that the device performs as intended under anticipated conditions of use, including device delivery, inflation, deflation, and removal.
(4) In vivo evaluation of the device must demonstrate device performance, including the ability of the device to treat aortic stenosis.
(5) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device.